BK Virus Infections Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | AlloVir, Amplyx Pharma, SL VAXiGEN

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, BK virus infections pipeline constitutes 4+ key companies continuously working towards developing 4+ BK virus infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The BK virus infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.


BK virus infections Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the BK virus infections Market.


Some of the key takeaways from the BK virus infections Pipeline Report:

Companies across the globe are diligently working toward developing novel BK virus infections treatment therapies with a considerable amount of success over the years. 
BK virus infections companies working in the treatment market are Orthogon Therapeutics, AiCuris, antibody Memo Therapeutics, SymBio Pharmaceuticals, Vera Therapeutics, AlloVir, and others, are developing therapies for the BK virus infections treatment 
Emerging BK virus infections therapies in the different phases of clinical trials are- BK virus antiviral therapy, AIC 468, AntiBKV, Brincidofovir, MAU868, ALVR 105, and others are expected to have a significant impact on the BK virus infections market in the coming years.   
In March 2021, In order to assess ALVR105 (Viralym-M), AlloVir started a Phase III research. This allogeneic, over-the-counter medication targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus
In January 2021, In order to determine the safety and effectiveness of posoleucel (ALVR105,Viralym-M) in preventing clinically significant viral infections caused by CMV, EBV, HHV-6, AdV, BKV, and JCV in high-risk alloHCT recipients, AlloVir started a clinical trial
In October 2021, Posoleucel (ViralymM, ALVR105) has been given Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA) in order to treat hemorrhagic cystitis (HC) caused by viruses. The critical need for additional therapeutic alternatives for patients who have undergone hematopoietic stem cell transplantation and are at risk for contracting viral infections and hemorrhagic cystitis is acknowledged by this orphan drug designation


BK virus infections Overview

BK virus (BKV) Infection: In 1971, the BK virus was discovered in the urine of a patient receiving a kidney transplant who also had ureteric stenosis. One of the 13 known polyomaviruses is the BKvirus. Around 80–90% of persons around the world have antibodies to BKV, which indicates exposure to or previous infection with the virus. BKV infection is either asymptomatic or accompanied by a mild flu-like symptoms at first.


Get a Free Sample PDF Report to know more about BK virus infections Pipeline Therapeutic Assessment- 



Emerging BK virus infections Drugs Under Different Phases of Clinical Development Include:

BK virus antiviral therapy: Orthogon Therapeutics
AIC 468: AiCuris
AntiBKV: antibody Memo Therapeutics
Brincidofovir: SymBio Pharmaceuticals
MAU868: Vera Therapeutics
ALVR 105: AlloVir
Viralym-M: AlloVir


Route of Administration

BK virus infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

Molecule Type


Molecule Type

Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Small molecule
Gene therapy
Product Type


BK virus infections Pipeline Therapeutics Assessment

BK virus infections Assessment by Product Type
BK virus infections By Stage and Product Type
BK virus infections Assessment by Route of Administration
BK virus infections By Stage and Route of Administration
BK virus infections Assessment by Molecule Type
BK virus infections by Stage and Molecule Type


DelveInsight’s BK virus infections Report covers around 4+ products under different phases of clinical development like-

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration


Further BK virus infections product details are provided in the report. Download the BK virus infections pipeline report to learn more about the emerging BK virus infections therapies


Some of the key companies in the BK virus infections Therapeutics Market include:

Key companies developing therapies for BK virus infections are – AlloVir, Amplyx Pharmaceuticals, SL VAXiGEN, Hybridize Therapeutics, and others.


BK virus infections Pipeline Analysis:

The BK virus infections pipeline report provides insights into 

The report provides detailed insights about companies that are developing therapies for the treatment of BK virus infections with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for BK virus infections Treatment.
BK virus infections key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
BK virus infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the BK virus infections market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.


Download Sample PDF Report to know more about BK virus infections drugs and therapies


BK virus infections Pipeline Market Drivers

Increase in the number of patients requiring kidney transplant worldwide, technological and medical advancements, guidelines supporting early detection and prompt diagnosis are some of the important factors that are fueling the BK virus infections Market.


BK virus infections Pipeline Market Barriers

However, lack of effective treatment options against BK virus infection, biology of BKPyV is not completely understood, side effects associated with the current treatment options and other factors are creating obstacles in the BK virus infections Market growth.


Scope of BK virus infections Pipeline Drug Insight    

Coverage: Global
Key BK virus infections Companies: Orthogon Therapeutics, AiCuris, antibody Memo Therapeutics, SymBio Pharmaceuticals, Vera Therapeutics, AlloVir, and others
Key BK virus infections Therapies: BK virus antiviral therapy, AIC 468, AntiBKV, Brincidofovir, MAU868, ALVR 105, and others
BK virus infections Therapeutic Assessment: BK virus infections current marketed and BK virus infections emerging therapies
BK virus infections Market Dynamics: BK virus infections market drivers and BK virus infections market barriers 


Request for Sample PDF Report for BK virus infections Pipeline Assessment and clinical trials


Table of Contents


BK virus infections Report Introduction


BK virus infections Executive Summary


BK virus infections Overview


BK virus infections- Analytical Perspective In-depth Commercial Assessment


BK virus infections Pipeline Therapeutics


BK virus infections Late Stage Products (Phase II/III)


BK virus infections Mid Stage Products (Phase II)


BK virus infections Early Stage Products (Phase I)


BK virus infections Preclinical Stage Products


BK virus infections Therapeutics Assessment


BK virus infections Inactive Products


Company-University Collaborations (Licensing/Partnering) Analysis


BK virus infections Key Companies


BK virus infections Key Products


BK virus infections Unmet Needs


BK virus infections Market Drivers and Barriers


BK virus infections Future Perspectives and Conclusion


BK virus infections Analyst Views




About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.


About DelveInsight


DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

%d bloggers like this: